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Abstract
Background: The HVP vaccine is a useful tool for preventing cervical cancer. The purpose of this
study is to determine the most frequent HPV genotypes in Equatorial Guinea in order to develop
future vaccination strategies to apply in this country.
Methods: A campaign against cervical cancer was carried out in the area on a total of 1,680
women. 26 of the women, following cytological screening, were treated surgically with a loop
electrosurgical excision procedure (LEEP). Cases were studied histologically and were genotyped
from paraffin blocks by applying a commercial kit that recognized 35 HPV types.
Results: Cytological diagnoses included 17 HSIL, 1 LSIL, 5 ASC-H and 3 AGUS. Histological
diagnosis resulted in 3 cases of microinvasive squamous cell carcinoma stage IA of FIGO, 9 CIN-3,
8 CIN-2, 2 CIN-1, 3 flat condylomas and mild dysplasia of the endocervical epithelium. Fifteen of
twenty-five cases genotyped were positive for HPV (60%). HPV 16 and 33 were identified in four
cases each, HPV 58 in two other cases, and HPV 18, 31, 52, and 82 in one case, with one HPV 16
and 58 coinfection.
Conclusion: The frequency of HPV types in the African area varies in comparison to other
regions, particularly in Europe and USA. Vaccination against the five most common HPV types (16,
33, 58, 18, and 31) should be considered in the geographic region of West Africa and specifically in
Equatorial Guinea.
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Background
Cervical cancer is the second most common malignancy
in women worldwide, and contributes to 9.8% of all
female cancers [1]. In sub-Saharan Africa, cervical cancer
is the leading cancer among women [2].
Human papillomaviruses (HPVs) are a group of viruses
associated with benign and malignant neoplasms of cuta-
neous and mucosal epithelia [3]. It is estimated that 6% of
the 9 million cancer cases registered each year worldwide
could be attributed to HPV infection [4]. The classified
high-risk HPVs (HR HPVs) are causally associated with
invasive cervical cancer, but they also seem to play a role
in the pathogenesis of other invasive cancers, including
the anus, vulva, esophagus and conjunctiva [5].
More than 100 HPV types have been identified, and about
40 can infect the genital tract [6]. Currently it is accepted
that all squamous cell cervical carcinomas contain at least
one of the 18 HPV considered oncogenic high-risk types
[7]. Fifteen of them have been ranked as "sure oncogenic
risk" types (HPVs 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 68, 73 and 82), and the other 3 have been classified as
"high probable oncogenic risk" types (HPVs 26, 53 and
66) [6].
HPV 16, HPV 18, HPV 31, HPV 58 and HPV 52 are the five
most common HPV types in cytologically normal women.
They also cause 50% of all HPV infections [1]. However,
certain HPV genotypes from cervical cytologic samples
vary highly between different geographical regions and
show a strong correlation with cervical cancer incidence
[8]. HPV 53 is included within the five HPV types most
commonly found in eastern Africa [1].
HPV has a strong association with cervical carcinoma and
its precursor lesions. In particular, the presence of HPV
precedes and predicts the development of a squamous
intraepithelial lesion (SIL) [9]. Among low grade squa-
mous intraepithelial lesions (LSILs) where HPV is present,
the most common types are HPV 16 (26.3%), HPV 31
(11.5%), HPV 51 (10.6%) and HPV 53 (10.2%). In Africa,
however, the probability for an HPV-positive LSIL to be
present with HPV type 16 is lower than in Europe [10].
Moreover, the progression of LSIL to a malignant lesion is
clearly different depending on the type of HPV infection.
Both LSIL HPV 18 positive or HPV 16 positive have a
higher probability of progression to cervical cancer than
those containing other types of HPV. As a result, it is very
important to know the type of HPV infection in order to
differentiate women with a high risk of developing cancer
from those with lower risk (who could be monitored care-
fully over a long period of time) [10].
Worldwide, HPV types 16 and/or 18 are detected in more
than 50% of all squamous intraepithelial high-grade
lesions (HSILs), 70% of infections are detected in invasive
cancer and 81.5% of infections are detected in adenocar-
cinomas [1]. In squamous cell carcinoma (SCC), the most
common HPV types are HPV 16 (54.3%), HPV 18
(12.6%), HPV 33 (4.3%), HPV 45 (4.2%), HPV 31
(4.2%), HPV 58 (3%), HPV 52 (2.5%) and HPV 35 (1%)
[10]. These types are found in 95% of SCC cases that are
positive for HPV DNA [6].
All of the above implies that an effective vaccine against
the five most common HPV types (16, 18, 33, 45 and 31)
could prevent approximately 90% of cervical cancer cases
that occur worldwide. However, regional variations in the
distribution of certain types of HPV should be considered
in the development of vaccines tailored to different geo-
graphic regions [6]. As a result, there is a need to study the
prevalence of different HPV types in different geographic
areas and, particularly, in less studied regions such as
Africa.
Methods
Specimen collection and diagnosis
Samples were obtained from a cervical cancer screening
campaign carried out on the island of Bioko (Equatorial
Guinea) between May and October 2006. The study
included a total of 1680 women between 15 and 71 years
of age. None of the women had been screened previously
for cervical cytological abnormalities or HPV infection.
Study procedures were approved by local authorities. An
informed consent was obtained and a face-to-face inter-
view was conducted, soliciting information on the
women's demographic characteristics and reproductive
history. A general physical and detailed gynecological
examination were also carried out. Following a visual
inspection of the neck of the uterus, exfoliated cervical cell
samples were obtained using the Papanicolaou method.
Cytological smears were analysed in Madrid (Spain).
Abnormalities were classified with the Bethesda classifica-
tion system as falling within normal limits or reactive cel-
lular changes (normal), atypical squamous cells of
undetermined significance (ASCUS), low-grade SIL
(LSIL), high-grade SIL (HSIL), or carcinoma.
In the second phase, we performed surgery on those
women cytologically diagnosed with ASCUS, high-grade
SIL, and carcinoma. Twenty-six out of thirty women
(between 22 and 68 years of age) were able to undergo
surgery. The surgical treatment chosen was loop dia-
thermy conization; that is, LEEP (Loop Electrosurgical
Excision Procedure). The surgical samples were obtained,
processed histologically and analyzed in Spain, showing aDiagnostic Pathology 2009, 4:31 http://www.diagnosticpathology.org/content/4/1/31
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high positive correlation between the cytological and
pathological final diagnosis.
Samples used for the detection and genotyping of HPV
were obtained from paraffin blocks. The lesion area of
each paraffin block was selected microscopically and
punches of the same size (1 mm × 7 mm). One to three
different samples were used to extract DNA. Twenty five
out of twenty six cases were HPV genotyped. The remain-
ing case ended after being histopathologically studied.
Detection and genotyping of HPV
Samples were shipped to Genomica Laboratory. HPV-
DNA was isolated with K proteinase.
The Clart® Human Papillomavirus (Genomica, Spain) kit
was used for HPV DNA genotyping. HPV testing was car-
ried out by personnel who had no knowledge of the sub-
ject's medical history or cytologic diagnosis.
All samples were analysed for the presence of the follow-
ing HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43,
44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71,
72, 73, 81, 82, 83, 84, 85 and 89.
HPV detection was conducted using PGMYO9/PGMY11
general consensus primers designed to amplify a 450 bp
HPV L1 gene fragment and two different controls:
genomic DNA and PCR to insure a feasible assay.
The detection of the amplified PCR product was per-
formed with a new technological platform using a low
density Microarray, anchored in 2 ml tube-AT tube. It
allows simultaneous detection of multiple molecular
markers in the L1 fragment of 35 different HPV types and
in the necessary controls to insure a feasible assay. Finally,
for each specific probe the array was printed in triplicate,
so each sample was identified in triplicate. The entire
process was carried out according to the manufacturer's
standard protocol.
PCR products were marked with biotin and, after amplifi-
cation, they hybridised with the respective probes in spe-
cific known AT tube areas. Biotin binds to streptavidin-
peroxidase after incubation. The addition of the TMB sub-
strate (3,3',5,5'-tetrametilbinzidine) generates an insolu-
ble product after hybridization.
The results were processed using a software program
which makes detection, interpretation and reporting for
each sample possible.
Second round of DNA extraction and PCR
The 10 negative samples for HPV detection were re-evalu-
ated. The initial DNA extraction and new samples for each
case were obtained, following the same procedures
explained above. For the new paraffin embedded samples
a commercially available tissue DNA extraction kit was
used (Biotools, Cat. No. 21.136/7).
125 ngm of nucleic acid was used for each 50 μl PCR reac-
tion with Taq DNA Polymerase (Perkin-Elmer Hispania).
Each PCR reaction contained primers for the intron E6 of
the HPV-16 or Beta-globin, following the the protocol
described by Shibata et al. (1988) [11]. Beta-globin was
used as a control gene. The primers had the following
sequence: E6 HPV-16 H1+5'ATTAGTGAGTATAGA
CATTA3'; H2 -5'GGCTTTTGACAGTTAATACA3' and B-
GLOBIN +5'GGTTGGCCAATCTACTCCCAGG3'; -5'GC
TCACTCAGTGTGGCAAAG3'. These primers generated
intron E6 and Beta-globin products of 109 and 536 base
pairs (bp), respectively. DNA for the HPV-16 was ampli-
fied for 35 cycles on a thermal cycler (Perkin-Elmer Cetus
Intruments, Techne).
The 50 μl DNA amplification reactions for HPV-16 con-
tained 2.5 μl of Buffer I (100 mM Tris-HCL pH 8.3, 500
mM KCl, 15 mM MgCl2, 0.01% (w/v) gelatin - Perkin
Elmer Hispania), 0.15 mM of the dNTP mixture, 15 pmol
of each primer, 2.5 units of Taq polymerase, and 1 μl of
DNA.
Before adding the enzyme, we did a hot start at 95°C for
10 min., followed by 35 cycles: 45 sec. at 96°C for denat-
uralization, 45 sec at 55°C for annealing, and 50 sec. at
72°C for extension, with a final extension step at 75°C for
10 min. A second PCR amplification was performed in the
same conditions with 1 μl of the previous product as a
template. The final product was detected in a 3% agarose
gel electrophoresis stained with ethidium bromide. Each
PCR reaction and the subsequent hybridization contained
negative and positive controls. The last one was a CIN-III,
positive for HPV-16 obtained by situ hybridization and
PCR amplification of the L1 region.
Results
Cytologic diagnoses included 17 cases of HSIL, 1 case of
LSIL, 5 cases of ASC-H and 3 cases of AGUS (Table 1). His-
topathological diagnoses resulted in 3 cases of microinva-
sive squamous cell carcinomas, 9 cervical intraepithelial
neoplasia CIN-3, 8 CIN-2, 2 CIN-1, 4 flat condylomas and
mild dysplasia of the endocervical epithelium (Table 2).
The pathologic examination of surgical specimens
showed a high positive correlation (84.6%) between pre-
cytological diagnoses and the final surgical pathology.
HPV DNA was detected in 60% of samples (Figures 1 and
2). The most frequently detected HPV types were HPV 16
(20% of the positive samples), HPV 33 (16%), HPV 58
(12%), HPV 18 (4%), HPV 31 (4%), HPV 52 (4%) andDiagnostic Pathology 2009, 4:31 http://www.diagnosticpathology.org/content/4/1/31
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HPV 82 (4%). We have also found one HPVs 16 and 58
coinfections belonging to a HSIL with CIN-3 (Table 3 and
Figure 3). In any case, all these HPV types are considered
high-risk oncogenic [6].
In the histological diagnosis we have detected HPV DNA
in all microinvasive squamous cell carcinomas. HPV 16,
HPV 33 and HPV 58 were found in these samples.
Cervical intraepithelial neoplasia (CIN-1, CIN-2 and CIN-
3) had HPV DNA in 63,2% of our cases. HPV 16 and 33
were the predominant types identified in each of the three
samples. These rates were followed in frequency by the
HPV 58, in two samples. Finally, each HPVs 18, 31, 52
and 82 were only found in one sample.
Twenty-five percent of flat condyloma or mild dysplasia
of the epithelium (one out of four samples) showed HPV
16. The cytologic diagnosis of this sample was ASC-H.
We have not found any of the 35 HPV genotypes in a high
percentage of samples. Since reactivity for the beta-globin
gene excluded DNA absence, we have analysed the most
prevalent HPV types and samples corresponding to differ-
ent cytological and histological diagnosis. Therefore, the
results could probably be due to the absence of HPV infec-
tion. However, presence of some other HPV type, not
detected by our method, or an HPV X should not be
rejected. The presence of an uncharacterized type (HPV X)
in the African continent has already been suggested in
another study in Kenya [2].
Discussion
In different African regions the prevalence of HPV in
women with normal cytology and, therefore, prone to cer-
vical cancer, is very high. In particular, the prevalence of
HPV in northern Africa (Morocco) was 21.5%, 31.6% in
East Africa (Kenya, Mozambique, Zimbabwe), 17% in
West Africa (Nigeria, Senegal) and 15.5% in southern
Africa (South Africa) [1].
It has been shown that women with cervical cancer in
Africa usually have the following HPV types, in descend-
ing order, 16, 18, 33, 45, 35, 31, 58, and 52. On the other
hand, HPVs 16, 33, 31, 18, 52, 58, 35 and 56 are those
most frequently present in women with HSIL [12].
We have found six of these types in our study (HPVs 16,
33, 58, 18, 31 and 52 in a prevalence order). Our results
reinforced the prevalence of 16 and 33 HPV types and
highlighted the high percentage of positive cases found
for HPV 58 (12%). We also highlight the lack of detection
of HPV 45, although its prevalence in cervical cancer has
been considered above average in Africa as compared to
other geographical areas.
A number of other papers has been published, determin-
ing the different HPV types in each African region. Analy-
sis of the data obtained is relevant for the design of
effective vaccines against cervical cancer in African
regions.
In Kenya (East Africa), a study was carried out on women
(with or without pathology) that were clients of a family
planning clinic. The study shows that the three most com-
mon HPVs types in women with HSIL were: HPVs 16
(37.7% of positive samples), HPV 52 (25.0%) and HPV
35 (17.9%). These researchers also reported an uncharac-
terized HPV type X in 15.8% of the positive samples [2].
Table 1: Cases by cytologic diagnosis
Cytologic diagnosis Number of women
ASCUS 39
ASC-H 7
LSIL 35
HSIL 19
Squamous Carcinoma 1
AGUS 3
Adenocarcinoma 0
Total pathological smears 104
Women needing surgery 30
Women not found 4
Women undergoing surgery 26
Table 2: Cases by histopathological diagnosis
Histopathological diagnosis Number of cases
Condyloma 4
Mild dysplasia of the endocervical epithelium 1
Cervical intraepithelial neoplasia (CIN-1) 2
Cervical intraepithelial neoplasia (CIN-2) 8
Cervical intraepithelial neoplasia (CIN-3) 8
Microinvasive squamous cell carcinoma-FIGO 1A 2
Microinvasive squamous cell carcinoma-FIGO IA1 1
Total 26Diagnostic Pathology 2009, 4:31 http://www.diagnosticpathology.org/content/4/1/31
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The existence of an HPV X could explain our undetected
HPV cases, although infection absence or HPV infection
of another undetected type by our method could also be
considered.
In another study from Kenya (East Africa), aimed at
women with invasive cervical carcinoma (ICC), the most
frequently HPV type detected was 16 (43.8% in HIV-neg-
ative and 41.2% in HIV-positive women). The second
most common type was HPV 18 (nearly 20% in HIV-neg-
ative and nearly 30% in HIV-positive). The most fre-
quently found types of HPV in HIV-negative women were
the following: HPV 45 (17.0%) and HPVs 35 and 52
(5.2% each). In HIV positive women, the most frequently
found types of HPV were: HPV 52 (19.6%) and HPVs 35,
45 and 56 (7.8% each) [13]. This study highlights HPV 45
detection in cases of ICC. Although considered quite prev-
alent in the African continent, it has not been detected in
our work.
HPV 35 was found slightly more often than HPV 16 in
Mozambique (southeast Africa), both in women with
normal cytology and in those with HSIL or more severe
Low-density array of negative control Figure 1
Low-density array of negative control. The signals 
belong to the internal genomic DNA integrity control probes 
and the plasmid that must be amplified in order to ensure 
both the correct PCR process and the absence of Taq 
polymerase inhibitors.
(A) Case of a 39 year old woman with Condyloma and the low-density array showing an infection with HPV 16 Figure 2
(A) Case of a 39 year old woman with Condyloma and the low-density array showing an infection with HPV 16. 
(B) Case of a 41 year old woman with a microinvasive carcinoma FIGO IA showing an infection with HPV 16. (C ) Case 
of a 33 year old woman with a CIN 3 and a co-infection with HPV 16 and 58. (D) Case of a 68 year old woman with a CIN 
3 and an infection with HPV 33. (E) Case of a 45 year old woman with microinvasive carcinoma and the low-density array 
showing an infection with HPV 58. (F) Case of a 39 year old woman with a CIN 3 showing an infection of HPV 31. Different 
geometric shapes includes spots corresponding to specific HPV cDNA.Diagnostic Pathology 2009, 4:31 http://www.diagnosticpathology.org/content/4/1/31
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neoplasms [14]. In South Africa, the most frequently
found virus in CIN cases was HPV 16 (44%), followed by
the HPV types 33 (22%), HPV 18 (19%) and HPV 35
(14%) [15].
In Senegal (northwest Africa), while the rate of LSIL
lesions were found to be associated with the detection of
HPV types 58 and 16, the risk of HSIL/cancer was found
to be associated mainly with the presence of infection
with some high-risk HPV types and, in particular, with
HPVs 16, 58, 33 and 52, and also with types 31 and 18
[16].
In Ivory Coast (West Africa) women with LSIL, the most
frequent HPVs were HPV 16 (12.2%), HPV 18 (6.9%),
HPV 31 and 33 (6.1% each) and HPV 70 (5.3%). In
women with HSIL from the same region, the most fre-
quent HPVs were HPV 16 (30.6%), HPV 18 (10.2%) and
HPVs 33, 58 and 70 (8.2% each) [17]. In Nigeria (West
Africa), the most commonly detected types of high-risk
HPV were 16 and 35, both in women with no pathology
and in women with dysplastic lesions, followed by HPVs
31, 58 and 56 [18].
To sum up, HPV types in women with cervical pathology
in Africa are somewhat different from those in Europe and
the USA, and they also vary in different regions of Africa.
The three most prevalent HPV types were 16, 58 and 33.
Other HPVs have appeared quite frequently in our study
and have also been persistently detected in previous stud-
ies: HPV 18, HPV 31 and HPV 52 (Table 4 and Figure 4).
The prevalence of HPV 16 in cervical cancer is higher in
Europe than in other continents. This may be due to the
fact that HPV 16 infection appears to be less favoured by
the deterioration of immune status. Therefore, defects in
cellular immunity (e.g., parasitic infestation, malnutrition
or HIV infection) could contribute to a different frequency
of HPV types in certain populations, i.e., those in Africa as
compared to other countries [12].
We have concluded that our results are in agreement with
studies published on this subject in recent years, and espe-
cially with studies in West Africa. We have found the same
six most prevalent HPV types in Senegal and Ivory Coast
(Table 4). Moreover, prevalence rates are somewhat simi-
lar, indicating the reliability of the data and the study
Table 3: HPV genotyping of samples
Sample Age Cytology Final Diagnosis HPV detected HPV not detected Beta-globin
16 18 31 33 52 58 82
1 41 HSIL Microinvasive carcinoma x
2 45 ASC-H Microinvasive carcinoma x
3 45 HSIL Microinvasive carcinoma x
43 3 H S I L C I N - 3 x x
56 8 H S I L C I N - 3 x
64 7 A G U S C I N - 3 x
7 39 ASC-H CIN-3 x
84 8 H S I L C I N - 3 x
95 0 H S I L C I N - 3 x +
10 33 HSIL CIN-3 x +
11 48 HSIL CIN-3 x +
12 46 HSIL CIN-2 x
13 48 HSIL CIN-2 x
14 34 ASC-H CIN-2 x
15 23 HSIL CIN-2 x
16 25 HSIL CIN-2 x
17 37 HSIL CIN-2 x
18 40 HSIL CIN-2 x +
19 30 HSIL CIN-2 x +
20 37 ASC-H CIN-1 x +
21 30 AGUS CIN-1 x +
22 41 AGUS Mild dysplasia endocervical x +
23 39 ASC-H Condyloma x
24 42 HSIL Condyloma x +
25 22 HSIL Condyloma x +
Total 5114131 1 0
% 20 4 4 16 4 12 4 40Diagnostic Pathology 2009, 4:31 http://www.diagnosticpathology.org/content/4/1/31
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method used. Differences found between these studies
and the one carried out in Nigeria could be due to the
lower severity of lesions. Other areas in which our study
overlaps with others include the minor prevalence of HPV
18 and a greater role played by other HPV types such as 58
and 33.
It is estimated that the currently available 16/18 HPVs vac-
cines could prevent some 350,000 cases of cervical cancer
annually. An extension to the following six most common
HPV types (31, 33, 35, 45, 52 and 58) could lead to an
increase in protection of about 90%, the equivalent of
440,000 cases of preventable cervical cancer per year. It
would be a good idea to take regional differences into
account when preparing for the inclusion of the HPVs
type [12], in case impossibilities arise that prevent the
inclusion of the six additional ones in the next genera-
tions of HPV vaccines.
Conclusion
As a result, in the African regions, where the prevalence of
different HPV types varies in comparison to what was
found elsewhere in the world and particularly in Europe
and the USA, the new vaccination strategies against HPV
should take into account the most prevalent HPV types in
a given population. In fact, other studies have suggested
the need to address the HPV 58 during the development
of the strategic approach for vaccination against cervical
cancer in the geographical region of northwest Africa
(Senegal) [16]. Thus, our study reinforces the suggestion
that vaccination against HPV 58, and also against HPVs 31
and 33, should be considered in the geographic region of
West Africa and specifically in Equatorial Guinea.
Strengths and weaknesses of the study
Our study gives a valuable description of the most preva-
lent HPV types in West Africa and confirms other studies
found in the same region. The results obtained are rele-
vant due to the scarcity of similar studies conducted in the
geographical area in which Equatorial Guinea is located.
In fact, the present study is the only one that has been car-
ried out in this country.
The difficulty of obtaining cases is an ostensible weakness
due to the number of cases we were, in the end, able to
study, as well as the affect this has on the study's signifi-
cance. It would be of interest to obtain more cases in the
future for further study.
Human Papillomavirus type distribution in West Africa Figure 4
Human Papillomavirus type distribution in West 
Africa.
Human Papillomavirus type distribution in Equatorial Guinea Figure 3
Human Papillomavirus type distribution in Equato-
rial Guinea.
Table 4: High-risk HPVs types more frequent in West Africa
Country Nigeria18 Senegal16 Ivory Coast17 Equatorial Guinea
Pathology Abnormal Cytology/VIA HSIL/cancer HSIL Abnormal cytology
HPV types 16 (7,8%) 16 (23,3%) 16 (30,6%) 16 (20%)
35 (7,8%) 58 (12,8%) 18 (10,2%) 33 (16%)
31 (7%) 33 (8,1%) 33 (8,2%) 58 (12%)
58 (6%) 52 (8,1%) 58 (8,2%) 18 (4%)
56 (5,7%) 31 (5,8%) 31 (6,1%) 31 (4%)
66 (5,2%) 18 (4,7%) 52 (4,1%) 52 (4%)
18. Thomas JO et al. Br J Cancer 2004.
16. Xi LF et al. Int L Cancer 2003.
17. La Ruche G et al. Int J Cancer 1998.Diagnostic Pathology 2009, 4:31 http://www.diagnosticpathology.org/content/4/1/31
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termined significance; LSIL: Low-grade squamous
intraepithelial lesion; HSIL: High-grade squamous
intraepithelial lesion; SCC/ICC: Squamous cell carci-
noma; invasive cervical carcinoma; CIN: Cervical intraep-
ithelial neoplasia; VIA: Visual inspection of the uterine
cervix with acetic acid.
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